{"id":63028,"date":"2022-04-29T12:18:15","date_gmt":"2022-04-29T10:18:15","guid":{"rendered":"https:\/\/blog.cofb.cat\/?p=63028"},"modified":"2023-10-05T08:10:27","modified_gmt":"2023-10-05T08:10:27","slug":"alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","title":{"rendered":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d’actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3"},"content":{"rendered":"\n

El passat 20 d’abril<\/strong> va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong> la tert\u00falia d’actualitat “Alzheimer i aducanumab. Controv\u00e8rsies”<\/strong>, a c\u00e0rrec de la Dra. Merc\u00e8 Boada<\/strong>, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE<\/a><\/strong> i el Dr. Albert Lle\u00f3<\/strong>, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l’Hospital de Sant Pau i coordinador del programa Alzheimer de CIBERNED. Aina Surroca<\/strong>, secret\u00e0ria de la Junta de Govern del COFB<\/strong> i responsable de la Comissi\u00f3 Delegada de Formaci\u00f3 Continuada<\/strong>, va ser l’encarregada de moderar la sessi\u00f3<\/strong>. <\/p>\n\n\n\n

\"D'esquerra
D’esquerra a dreta: La Dra. Merc\u00e8 Boada, el Dr. Albert Lle\u00f3 i la secret\u00e0ria de la Junta de Govern del COFB, Aina Surroca. <\/figcaption><\/figure>\n\n\n\n

Alzheimer, aducanumab i altres f\u00e0rmacs<\/strong><\/h2>\n\n\n\n

Una nova era pel tractament de l’Alzheimer<\/strong> <\/span><\/strong><\/h3>\n\n\n\n

Segons va exposar el Dr. Lle\u00f3, “estem en un moment molt excitant de la hist\u00f2ria <\/strong>de la malaltia d’Alzheimer<\/strong> perqu\u00e8 realment hi ha hagut molts canvis<\/strong>. Cal posar en context on estem amb l’aducanumab<\/strong> i amb la resta de tractaments<\/strong>“. I va afegir: “Ens trobem en una era en qu\u00e8 sobretot hi ha f\u00e0rmacs biol\u00f2gics<\/strong> fonamentalment perqu\u00e8 en les estrat\u00e8gies pr\u00e8vies d’inhibici\u00f3 de vies productores d’amiloide i altres dianes no han mostrat resultats positius”. <\/p>\n\n\n\n

Aix\u00ed mateix, el Dr. Lle\u00f3 va apuntar que “a Europa, el 17 de desembre, l’Ag\u00e8ncia Europea del Medicament<\/strong> (EMA, per les seves sigles en angl\u00e8s) es va pronunciar i va dir que no aprovaria, que no autoritzaria l’\u00fas a Europa del f\u00e0rmac aducanumab<\/strong>“. <\/p>\n\n\n\n

\"El
El Dr. Albert Lle\u00f3, durant la tert\u00falia d’actualitat. <\/figcaption><\/figure>\n\n\n\n

En aquest sentit, segons va exposar el doctor “la companyia est\u00e0 preparant una apel\u00b7laci\u00f3<\/strong> i no hi ha una resoluci\u00f3 definitiva<\/strong>. Per\u00f2 la resoluci\u00f3 inicial va ser negativa i la companyia, arran d’aquesta situaci\u00f3, decideix iniciar -per recomanaci\u00f3 de la FDA i d’experts independents- un nou estudi confirmatori<\/strong> amb aducanumab<\/strong>, en fase 3b\/4<\/strong>, amb m\u00e9s de 1.500 pacients<\/strong> amb Alzheimer d’entre 60 i 85 anys<\/strong>, ja que sembla que els pacients m\u00e9s grans tenen major resposta que els pacients m\u00e9s joves”. <\/p>\n\n\n\n

A banda de l’aducanumab<\/strong>, el doctor va detallar que “hi ha altres f\u00e0rmacs<\/strong> que estan a la fase final, la fase 3. De fet, n’hi ha alguns que ja han tingut resultats positius en estudis previs com lecanemab<\/strong>, donanemab<\/strong> o gantenerumab<\/strong>. Alguns d’ells acabaran la fase 3 complerta a finals d’any. O sigui, entre finals d’aquest i a principis de l’any vinent tindrem not\u00edcies i ser\u00e0 molt important. I tots ells tenen dades que hi ha una certa senyal cl\u00ednica <\/strong>en les fases pr\u00e8vies”. <\/p>\n\n\n\n

Finalment, el Dr. Lle\u00f3<\/strong> va concloure que “el tractament de l’Alzheimer ha entrat en una nova era<\/strong> i que, malgrat la controv\u00e8rsia<\/strong>, s’ha aprovat el primer biol\u00f2gic per a l’Alzheimer<\/strong>. Hi ha altres biol\u00f2gics<\/strong> que estan a l’horitz\u00f3 <\/strong>i que \u00e9s q\u00fcesti\u00f3 de temps que aix\u00f2 arribi a Europa. Crec que ara disposem d’un temps d’or realment per preparar el terreny<\/strong> perqu\u00e8 estiguem preparats tant els hospitals com els diferents centres, tant en el diagn\u00f2stic com a l’hora d’adequar les infraestructures per preparar-nos per una nova era<\/strong> en la malaltia d’Alzheimer<\/strong>“.<\/p>\n\n\n\n

La proximitat del farmac\u00e8utic i el seu coneixement del malalt.<\/span><\/strong><\/h3>\n\n\n\n

La Dra. Boada<\/strong> durant la seva intervenci\u00f3<\/strong> va afirmar que la definici\u00f3 de malaltia d’Alzheimer<\/strong> ha canviat: “Deixem de parlar de dem\u00e8ncia tipus Alzheimer<\/strong>, que \u00e9s el que f\u00e8iem, per parlar de malaltia d’Alzheimer<\/strong>. Aquesta \u00faltima <\/strong>est\u00e0 focalitzada en buscar aquells marcadors biol\u00f2gics <\/strong>que indiquin que el cervell t\u00e9 la marca que la ci\u00e8ncia ha dit que configurava aquesta malaltia. <\/p>\n\n\n\n

\"La
La Dra. Merc\u00e8 Boada, en un moment de la seva intervenci\u00f3.<\/figcaption><\/figure>\n\n\n\n

Respecte a la controv\u00e8rsia amb l’aducanumab<\/strong>, en una malaltia tan llarga com l’alzheimer, la directora m\u00e8dica de la Fundaci\u00f3 ACE va recordar que “en 6 mesos de tractament no podem veure res<\/strong>“. Malgrat aix\u00f2, “hem de fer passos petits, i si b\u00e9, el benefici cl\u00ednic que tenim per ara \u00e9s minso, ens va molt b\u00e9 per entendre la malaltia des d’un punt de vista biol\u00f2gic<\/strong>“.<\/p>\n\n\n\n

Pel que fa al paper dels farmac\u00e8utics<\/strong>, la Dra. Boada va explicar que aquests professionals sanitaris “ens poden ajudar, s\u00f3n els que coneixen m\u00e9s el malalt. La farm\u00e0cia<\/strong> \u00e9s extremadament propera<\/strong>“.<\/p>\n\n\n

\n\n\n

Segons l’EMA, l’evid\u00e8ncia cient\u00edfica<\/strong> no demostra prou que l’aducanumab<\/strong> sigui efectiu per al tractament en adults en fases inicials de la malaltia d’Alzheimer<\/strong>. L’ag\u00e8ncia europea ha concl\u00f2s que, malgrat que el f\u00e0rmac ha demostrat reduir la pres\u00e8ncia d’amiloide al cervell, la investigaci\u00f3 actual no relaciona aquest fet amb una millora cl\u00ednica dels pacients.<\/p>\n\n\n\n

L’autoritzaci\u00f3 d’aducanumab als EUA est\u00e0 subjecta a un nou estudi postcomercialitzaci\u00f3 <\/strong>per demostrar-ne l’efic\u00e0cia cl\u00ednica. A Europa, s’ha decidit que no queda demostrat que els possibles beneficis superin els possibles riscos. De moment, la farmac\u00e8utica Biogen ha comunicat que demanar\u00e0 que reexaminin la sol\u00b7licitud a Europa.<\/p> <\/div>\n","protected":false},"excerpt":{"rendered":"

El passat 20 d’abril va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la tert\u00falia d’actualitat “Alzheimer i aducanumab. Controv\u00e8rsies”, a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i el Dr. Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei […]<\/p>\n","protected":false},"author":1,"featured_media":67922,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[512,64,18,19,53,68,69,70,684,76,140,141],"class_list":["post-63028","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-alzheimer","tag-atencio-farmaceutica","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-farmaceutics","tag-farmacia","tag-farmacia-comunitaria","tag-formacio","tag-memoria","tag-oficina-de-farmacia","tag-tertulia-dactualitat","tag-tertulies-dactualitat"],"yoast_head":"\nAlzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat "Alzheimer i aducanumab. Controv\u00e8rsies", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat "Alzheimer i aducanumab. Controv\u00e8rsies", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-29T10:18:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-05T08:10:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/novaorg.cofb.net\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d’actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3\",\"datePublished\":\"2022-04-29T10:18:15+00:00\",\"dateModified\":\"2023-10-05T08:10:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\"},\"wordCount\":907,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\",\"keywords\":[\"alzheimer\",\"Atenci\u00f3 farmac\u00e8utica\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"farmac\u00e8utics\",\"Farm\u00e0cia\",\"farm\u00e0cia comunit\u00e0ria\",\"Formaci\u00f3\",\"Mem\u00f2ria\",\"Oficina de farm\u00e0cia\",\"tert\u00falia d'actualitat\",\"tert\u00falies d'actualitat\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\",\"name\":\"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\",\"datePublished\":\"2022-04-29T10:18:15+00:00\",\"dateModified\":\"2023-10-05T08:10:27+00:00\",\"description\":\"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat \\\"Alzheimer i aducanumab. Controv\u00e8rsies\\\", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d’actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat \"Alzheimer i aducanumab. Controv\u00e8rsies\", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","og_locale":"ca_ES","og_type":"article","og_title":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat \"Alzheimer i aducanumab. Controv\u00e8rsies\", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.","og_url":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2022-04-29T10:18:15+00:00","article_modified_time":"2023-10-05T08:10:27+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/novaorg.cofb.net\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","type":"image\/jpeg"}],"author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"5 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d’actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3","datePublished":"2022-04-29T10:18:15+00:00","dateModified":"2023-10-05T08:10:27+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/"},"wordCount":907,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","keywords":["alzheimer","Atenci\u00f3 farmac\u00e8utica","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","farmac\u00e8utics","Farm\u00e0cia","farm\u00e0cia comunit\u00e0ria","Formaci\u00f3","Mem\u00f2ria","Oficina de farm\u00e0cia","tert\u00falia d'actualitat","tert\u00falies d'actualitat"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","url":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","name":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","datePublished":"2022-04-29T10:18:15+00:00","dateModified":"2023-10-05T08:10:27+00:00","description":"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat \"Alzheimer i aducanumab. Controv\u00e8rsies\", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d’actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",1024,576,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1-300x169.jpg",300,169,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1-768x432.jpg",768,432,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",1024,576,false],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",1024,576,false],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",1024,576,false],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",18,10,false]},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 20 d’abril va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la tert\u00falia d’actualitat “Alzheimer i aducanumab. Controv\u00e8rsies”, a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i el Dr. Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/63028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=63028"}],"version-history":[{"count":2,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/63028\/revisions"}],"predecessor-version":[{"id":68737,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/63028\/revisions\/68737"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/67922"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=63028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=63028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=63028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}